CABG-procedures in patients with pretreatment with the GPIIb/IIIa-receptor antagonist tirofiban (Aggrastat©): Modification of perioperative management?

Boeken, Udo; Litmathe, Jens; Kurt, Muhammed; Feindt, P.; Gams, E.

doi:10.1016/j.ijcard.2007.02.062

Cited by 7 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…75 In a small retrospective study, tirofiban-treated patients having CABG showed more bleeding than patients without tirofiban, but no difference was found between different discontinuation times. 76 In conclusion, GPIIb/IIIa inhibitor discontinuation at least 4 h before surgery should be considered to minimize the risk of post-operative bleeding.…”

Section: Glycoprotein Iib/iiia Inhibitorsmentioning

confidence: 99%

2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery

Boer¹,

Meesters²,

Milojevic³

et al. 2018

Journal of Cardiothoracic and Vascular Anesthesia

346

192

View full text Add to dashboard Cite

Section: Glycoprotein Iib/iiia Inhibitorsmentioning

confidence: 99%

2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery

Boer¹,

Meesters²,

Milojevic³

et al. 2018

Journal of Cardiothoracic and Vascular Anesthesia

346

192

View full text Add to dashboard Cite

“…The recovery of platelet functions is obtained within 24-48 h for abciximab and 4-8 h for eptifibatide and tirofiban [31]. In a small retrospective study, tirofiban-treated patients having CABG showed more bleeding than patients who were not treated with tirofiban, but there was no difference between different discontinuation times [32]. Discontinuation of GPIIb/ IIIa inhibitor at least 4 h before surgery should be considered to minimize the risk of postoperative bleeding.…”

Section: Glycoprotein Iib/iiia Inhibitorsmentioning

confidence: 99%

Hemostasis in Cardiac Surgery: How We Do it with Limited Resources

Türker¹

2019

Biosurgicals - The Next Frontier in Operative Approaches [Working Title]

View full text Add to dashboard Cite

Hemostasis in cardiac surgery is still a severe problem for surgeons. Blood and its products are the most valuable at the same time dangerous arms of surgeons. Industries produced many biological or non-biological products, which increase the cost of operations, are available for this issue. Decision making and producing solutions must be the most important properties of a cardiac surgeon. In any condition and resources, true strategy and patience will bring the success. Antiaggregants and anticoagulants are widely used agents, and in emergency or early cases, surgeons have to operate these patients. Both groups of drugs are growing, and in an emergency position, it is hard to know which drugs the patient using or given and what kind of medical status he/she has. For example non vitamin-K oral anticoagulants newer drugs and not known so much except cardiologists and cardiovascular surgeons. Simple solutions may have better results. Of course, in some conditions, urgent consultation can solve the problem. Cardiac surgeons have to figure out the problem by using their experience and surgical materials. Working as a team is a big advantage, more than one surgeon, experienced operation nurses and closer follow up in intensive care unit.

show abstract